St. Jude Agrees To Pay $39m To Settle Shareholder Suit
Executive Summary
The settlement, which does not include an admission of fault, puts an end to a long-running class action claim filed by investors who say they were misled by St. Jude’s failure to announce FDA safety concerns around the company’s Durata heart leads.
You may also be interested in...
HRS 2018 Wrap-Up: Tendril Lead Failures; Metaanalysis Of Contact-Force Catheter; LuxCath's OmniView; More Micra Results
The 2018 Heart Rhythm Society scientific sessions in Boston covered a variety of presentations of new electrophysiology clinical data, including a report on the failure of St. Jude's Tendril leads, a meta-analysis of contact-force catheters for atrial-fibrillation ablation, and new data on Medtronic's Micra leadless pacemaker.
The Rumors Were True: Abbott Buys St. Jude For $25b To Create Third Cardiovascular Giant
Abbott Laboratories has agreed to acquire St. Jude Medical for $25bn, creating a third player, along with Boston Scientific and Medtronic, that competes in all major sectors of the cardiovascular device business.
Another St. Jude ICD Lead Recall, But Impact May Be Limited
The recall, related to a manufacturing misstep for St. Jude's Optisure defibrillator leads, effects 447 devices and has not been linked to any patient injuries, the firm says.